SCHEMBL23828686

SCHEMBL23828686

COC(=O)c1ccc(COc2ccccc2CN2CCN(Cc3ccc4[nH]c(-c5ccccc5)nc4c3)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
NPC1 O15118 1/20 0.48
PKM P14618 1/20 0.48
HPGD P15428 1/20 0.48
NFKB1 P19838 1/20 0.48
RAB9A P51151 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
HDAC6 Q9UBN7 3/20 0.44
PDE4A P27815 1/20 0.44
PDE4B Q07343 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19982681 0.93 HDAC6 (0.50) LMNAKDM4EALDH1A1NPC1PKM
SCHEMBL19970886 0.92 KIT (0.44) LMNAKDM4EALDH1A1NPC1PKM
SCHEMBL19970844 0.92 LMNA (0.46) LMNAKDM4EALDH1A1NPC1PKM
SCHEMBL19970822 0.92 LMNA (0.45) LMNAKDM4EALDH1A1NPC1PKM
SCHEMBL19970765 0.90 SLC2A1 (0.41) LMNAKDM4EALDH1A1NPC1PKM
SCHEMBL19970852 0.90 LMNA (0.42) LMNAKDM4EALDH1A1NPC1PKM
SCHEMBL19970846 0.87 MGLL (0.50) LMNAKDM4EALDH1A1NPC1PKM
SCHEMBL19970802 0.86 MEN1 (0.43) LMNAKDM4EALDH1A1NPC1RAB9A
SCHEMBL19970887 0.86 HDAC6 (0.44) LMNAKDM4EALDH1A1NPC1PKM
SCHEMBL19970823 0.85 SLC2A1 (0.49) LMNAKDM4EALDH1A1NPC1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-10-25 US disclosed
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION FIP1L1, ZC3HAV1, MAVS LMNA 614/4885KDM4E 1873/4885ALDH1A1 1822/4885
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection FIP1L1, ZC3HAV1, MAVS LMNA 614/4885KDM4E 1873/4885ALDH1A1 1822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.